Eagle Pharmaceutical listed on the NASDAQ in 2014. In November 2023, the company announced a delay to 3Q23 results owing to potential adjustments of approximately US$15-20m related to returns and price adjustments stemming from slower than anticipated sales predominantly due to the expiry of inventory relating to its cancer drug. The adjustments potentially wiped out the entirely of profits for the year. In November, the company's CEO resigned followed by an announcement in December that these adjustments might lead to the restating of 2Q23 results as well. The company entered technical default in January (although it received a waiver), its CFO resigned in March, closely followed by a notice that it would be unable to publish FY23 results. Eagle would appear to have engaged in fraudulent behaviour although the extent is unclear at this stage.

The information on this page has been compiled from publicly available sources. GMT Research Limited has not verified the information and does not warrant its accuracy. Any claims made or views expressed are not necessarily those of GMT Research Limited.